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Background: Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a
monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow
transferrin-mediated iron transport to the bone marrow. This multicenter, phase 1 study evaluated the safety,
pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of a fully humanized mAb (LY2787106) with high
affinity for hepcidin in cancer patients with anemia.
Methods: Thirty-three patients with hepcidin levels ≥5 ng/mL received LY2787106 either every 3 weeks (19 patients,
dose range 0.3–10 mg/kg) (part A) or weekly (14 patients, dose 10 mg/kg) (part B). LY2787106 PK/PD markers of iron
and hematology biology were measured.
Results: LY2787106 clearance (32 mL/h) and volume of distribution (7.7 L) were independent of dose and time,
leading to a dose-proportional increase in concentration with dose. Consistent dose-dependent increases in serum
iron, and transferrin saturation were seen at the 3 and 10 mg/kg dose levels, typically peaking within 24 h after
LY2787106 administration and returning to baseline by day 8.
Conclusions: Our findings indicate that LY2787106 was well tolerated in cancer patients with anemia and that
targeting the hepcidin-ferroportin pathway by neutralizing hepcidin resulted in transient iron mobilization, thus
supporting the role of hepcidin in iron regulation.
Trial registration: ClinicalTrial.gov, NCT01340976
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Anemia is common in cancer patients, with a prevalence
of 30 to 90% depending upon disease stage and the
hemoglobin level used to define anemia [1]. It causes fa-
tigue, dyspnea, and other related symptoms that signifi-
cantly lower the quality of life and functional capacity of
patients with cancer. Furthermore, in one systematic re-
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[2]. The pathophysiology of anemia in cancer is complex
and has been attributed to inflammation that leads to in-
creased levels of cytokines that impair the production of
hematopoietic growth factors, including erythropoietin,
and the bone marrow response to erythropoietin [3].
A common limiting factor in red blood cell (RBC) pro-
duction is the macrophage’s failure to release sufficient iron
for erythroid progenitor cells. Hepcidin is a 25-amino-acid
peptide that binds to ferroportin and causes internalization
and degradation of the hepcidin-ferroportin complex,
leading to decreased iron absorption and reduced iron ex-
port from macrophages [4]. High hepcidin levels are found
in cancer patients and implicated in anemia pathogenesisle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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monoclonal antibody will prevent internalization of ferro-
portin, restore iron efflux from macrophages, and allow
transferrin-mediated iron transport to the bone marrow to
support erythropoiesis.
LY2787106 is a fully humanized monoclonal antibody
with high affinity for human hepcidin. In this first-in-
human phase 1 study, the safety, pharmacokinetics (PK),
pharmacodynamics (PD), and efficacy (effects on serum
iron panel, reticulocytes, and hemoglobin) of LY2787106
were evaluated in cancer patients with anemia.Methods
Study design
This was a multicenter phase 1 study in anemic patients
with cancer and measurable serum hepcidin levels (assay
sensitivity, ≥5 ng/mL). The study had two parts. In part A,
the primary objective was to assess the safety of
LY2787106 over the dosing range (0.3–10 mg/kg intraven-
ously (IV) every 3 weeks (Q3W)). In part B, the primary
objective was to assess mean change in hemoglobin from
baseline to end of week 12 following LY2787106 treatment
(10 mg/kg IV weekly) with and without oral iron supple-
mentation. Secondary objectives were to characterize the
PK of LY2787106 and to characterize PD changes in
serum iron panel measures, reticulocyte count, reticulo-
cyte hemoglobin content (CHr), and hemoglobin levels
after administration of LY2787106.
In part A, an open-label 3 + 3 dose escalation design
was used to evaluate the safety and PK and PD effects of
LY2787106. In part B, a modified 3 + 3 safety lead-in de-
sign was used to enroll patients to once-weekly dosing
with LY2787106 without oral iron supplementation be-
fore opening enrollment into two separate cohorts that
received the study drug with and without oral iron, re-
spectively. All patients entered follow-up once study
drug treatment was discontinued.
This study was conducted in accordance with the Inter-
national Conference on Harmonisation Guidelines for
Good Clinical Practice and the Declaration of Helsinki
after approval by each site’s institutional review board. All
patients gave written informed consent before undergoing
any study-specific procedures. This study was registered
at www.clinicaltrials.gov as #NCT01340976.Patient population
Eligible patients were ≥18 years old with previously
treated metastatic or incurable nonmyeloid cancers,
hemoglobin <11 g/dL, serum hepcidin levels ≥5 ng/mL
(serum hepcidin levels in normal individuals and patients
have been previously described [8]), and Eastern Coopera-
tive Oncology Group (ECOG) performance status ≤2.
Treatment with chemotherapy was permitted during thecourse of the clinical trial. A full list of inclusion and ex-
clusion criteria is available in Additional file 1.
Treatment
Part A (dose escalation)
Patients in part A received LY2787106 IV at a dose of 0.3,
1, 3, or 10 mg/kg over 30 min. The first cycle defined the
period that governed dose escalation. The criteria for
dose-limiting toxicities (DLTs) included any clinically sig-
nificant grade ≥2 toxicity or other event deemed signifi-
cant by the investigator, grade ≥3 anemia (excluding
patients with baseline <9.0 g/dL) or hemoglobin decrease
>1.0 g/dL if baseline hemoglobin was <9.0 g/dL (con-
firmed by two independent measurements), grade ≥3
cytokine release syndrome/acute infusion reaction, or
other grade ≥3 hematological toxicity. Stopping rules are
described in Additional file 1. The maximum tolerated
dose (MTD) for LY2787106 was defined as the highest
tested dose below the level at which at least one third of
patients experienced a DLT.
Patients who had no DLT; met no stopping rules; and
had increased serum iron, transferrin saturation (TSAT),
reticulocyte count, or hemoglobin levels after the initial
dose were allowed to receive up to two additional doses
at 3-week intervals at the investigator’s discretion.
Part B
Interim analysis of part A results showed that LY2787106
given Q3W was well tolerated, had a short half-life (t1/2)
(~7 days), and led to transiently increased serum iron levels;
therefore, the decision was made to use once-weekly dosing
in part B. In addition, part B was revised to enroll an
additional cohort of patients who would receive oral iron
supplementation to determine the safety of the combin-
ation and to explore whether oral iron therapy can augment
the effects of LY2787106 on iron-restricted anemia.
Patients in part B received eight weekly doses of
10 mg/kg LY2787106 given IV over 30 min with or with-
out daily oral iron supplementation (65–72 mg elemen-
tal iron daily) (cohorts B2 and B1, respectively). Patients
who met no stopping rules and were considered to be
benefiting during the defined treatment period were
allowed to receive up to eight additional weekly doses at
the investigator’s discretion. The primary efficacy end-
point was mean change in hemoglobin level from base-
line to the end of cycle 4 (i.e., week 12).
Safety assessments
Adverse events were collected and graded according to
National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI CTCAE) version 3.0 and, when
necessary, the Medical Dictionary for Regulatory Activities
(MedDRA) version 17.1. Laboratory monitoring included
hematology, chemistry, urinalysis, biomarkers, iron panel,
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lected laboratory results of interest included serum iron,
serum hepcidin, hemoglobin, reticulocyte count, TSAT,
interleukin-6 (IL-6), serum erythropoietin, ferritin, CHr,
soluble transferrin receptor, tumor necrosis factor-α
(TNF-α), C-reactive protein, total iron binding capacity
(TIBC), and immunogenicity data.
Pharmacokinetic assessments
Pharmacokinetic analysis was conducted on serum sam-
ples from patients in parts A and B who had received at
least one dose of LY2787106 and had sufficient postdose
samples collected to allow estimation of PK parameters.
Serum LY2787106 concentrations were determined by a
validated enzyme-linked immunosorbent assay (ELISA).
Maximum concentration (Cmax), area under the
concentration-time curve (AUC), half-life (t1/2), volume
of distribution (Vd), clearance (CL), and other relevant
parameters of LY2787106 were calculated as applicable.
Pharmacodynamic assessments
Pharmacodynamic changes from baseline after adminis-
tration of LY2787106 were analyzed for key parameters in-
cluding serum iron, ferritin, TSAT, reticulocyte count,
hemoglobin, and serum hepcidin. Other PD parameters
analyzed were IL-6, TNF-α, C-reactive protein, and
erythropoietin.
Statistical analyses
The total sample size for this study was determined by
the incidence of DLTs (at least 3 evaluable patients per
dose cohort and up to 6 patients per dose group in part
A prior to establishing the MTD). In part B, the plan
was to treat approximately 32 patients so that each ofFig. 1 Study flow diagramcohorts B1 and B2 would have at least 12 evaluable pa-
tients, assuming an approximately 25% early dropout
rate. Assuming an improvement in mean hemoglobin of
0.75 g/dL from baseline to the end of cycle 4 and a
standard deviation in hemoglobin change of 1.5 g/dL, a
sample size of 12 patients in each cohort in part B was
determined to have 80% power to detect a statistically
significant increase in hemoglobin with a 1-sided type I
error rate of 0.20.
Safety analyses were based on data from all patients
who had received at least one dose of LY2787106 (safety
population). Efficacy analysis in part B was based on data
from patients who had received all four of the first four
weekly doses of LY2787106 (evaluable population), were
at least 60% compliant with oral iron therapy during the
first 4 cycles of LY2787106 (cohort B1 only), and had
hemoglobin assessed after each of the first four doses.
The primary efficacy analysis (part B only) estimated and
compared mean changes in hemoglobin from baseline to
the end of cycle 4 with the hypothesized null control
using a 1-sided 80% confidence interval (CI) (equivalent
to a 2-sided 60% CI), based on a t distribution. For co-
horts B1 and B2, estimates and 2-sided 90% CIs were
calculated for the least-squares mean of hemoglobin
changes by the repeated-measures method (linear
mixed-effects model with baseline value and time as
covariates) at each assessment time point and for the
AUC for hemoglobin change during the postbaseline
treatment period (week 12); the estimates were then
compared between the two cohorts.
Pharmacokinetic parameters were computed by stand-
ard noncompartmental analysis methods. Data were also
analyzed using nonlinear mixed-effect modeling (as im-
plemented in NONMEM). Data from all patients were
Table 1 Baseline and disease characteristics by dosing group
Part A Part B Total
















Age, years 64.5 (58–75) 76.7 (63–88) 62.1 (44–78) 63.2 (53–75) 66.3 (50–79) 62.7 (51–72) 64.9 (44–88)
Sex
Men 2 (50) 2 (67) 3 (43) 2 (40) 3 (43) 1 (14) 13 (39)
Women 2 (50) 1 (33) 4 (57) 3 (60) 4 (57) 6 (86) 20 (61)
Race
White 4 (100) 3 (100) 5 (71) 3 (60) 5 (71) 5 (71) 25 (76)
Black or African American 0 0 2 (29) 1 (20) 2 (29) 2 (29) 7 (21)
Asian 0 0 0 1 (20) 0 0 1 (3)
ECOG performance status
0 1 (25) 1 (33) 2 (29) 0 0 0 4 (12)
1 3 (75) 2 (67) 3 (43) 5 (100) 7 (100) 6 (86) 26 (79)
2 0 0 2 (29) 0 0 1 (14) 3 (9)
Prior cancer treatment
Systemic chemotherapy 4 (100) 3 (100) 7 (100) 5 (100) 5 (71) 4 (57) 28 (85)
Radiotherapy 1 (25) 1 (33) 2 (29) 3 (60) 2 (29) 5 (71) 14 (42)
Surgery 3 (75) 1 (33) 2 (29) 2 (40) 1 (14) 2 (29) 11 (33)
Median no. of prior oncology treatments 9.5 4.0 6.0 5.0 2.0 1.5 4.5
Mean serum hepcidin (ng/mL) 24.9 (18.51) 12.2 (8.48) 36.4 (21.87) 51.1 (39.81) 45.4 (20.23) 39.7 (38.99) 37.6 (28.46)
Mean hemoglobin (g/dL) 9.1 (1.45) 8.9 (0.91) 8.5 (0.83) 9.8 (0.84) 9.4 (1.13) 9.5 (0.31) 9.2 (0.95)
Mean erythropoietin (mIU/mL) 141.3 (92.71) 42.0 (20.16) 103.2 (135.14) 94.4 (116.49) 70.0 (60.87) 46.1 (25.67) 81.8 (88.29)
Mean serum ferritin (μg/L) 779.0 (303.64) 237.2 (136.68) 667.1 (683.65) 263.7 (178.90) 714.6 (553.58) 289.0 (175.70) 510.3 (464.15)
Cancer type
Multiple myeloma 1 (25) 0 2 (29) 3 (60) 3 (43) 3 (43) 14 (42)
Breast cancer 0 0 0 1 (20) 3 (43) 0 4 (12)
Othera 3 (75) 3 (100) 5 (71) 1 (20) 1 (14) 4 (57) 15 (46)
Values shown are for the safety population (i.e., all patients who received at least one dose of LY2787106 [n = 33]). Data are mean (range) for age;
median for number of prior oncology treatments; mean (SD) for serum hepcidin, hemoglobin, erythropoietin, and serum ferritin; and n (%) for all
other parameters
ECOG Eastern Cooperative Oncology Group
a“Other” cancer types include Waldenstrom’s macroglobulinemia (2 patients), pancreatic adenocarcinoma (2 patients), rectal cancer (2 patients), renal
cell carcinoma, metastatic prostate cancer, colon adenocarcinoma, unknown primary presumed ovarian adenocarcinoma, metastatic sarcomatoid
carcinoma of the distal esophagus, non-small cell lung cancer, adenocarcinoma of lung, gastrointestinal stromal tumor, and adenocarcinoma of
the liver
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parameters and between- and within-patient variability.
The primary parameters analyzed were Cmax and AUC of
LY2787106. Other parameters analyzed were t1/2, Vd, and
CL. The primary parameters (Cmax and AUC) were evalu-
ated statistically to delineate the effects of dose proportion-
ality using methods described previously [9]. Least-square
estimates of geometric means and corresponding 90% CIs
were determined for each dose, together with the dose-
normalized ratio of geometric means and CIs.
The absolute percent change from baseline for all PD
and immunogenicity endpoints was summarized foreach cohort and each sample day or time combination,
and the maximum change over the entire study was
determined.
Results
Baseline and patient characteristics
Between 19 January 2010 and 10 December 2014, a
total of 33 patients were enrolled: 19 patients in part A
and 14 patients in part B (7 patients each in cohorts B1
and B2) (Fig. 1). Table 1 summarizes their baseline and
disease characteristics. Patients received a median of 4.5
prior oncology treatments. Overall, mean (SD) hemoglobin
Table 2 Treatment-emergent adverse events regardless of causality reported by ≥10% of patients on LY2787106 (safety population)

















Fatigue 0 1 (33.3) 2 (28.6) 0 5 (71.4) 7 (100) 15 (45.5)
Nausea 1 (25.0) 1 (33.3) 2 (28.6) 1 (20.0) 3 (42.9) 4 (57.1) 12 (36.4)
Dyspnea 1 (25.0) 0 0 0 4 (57.1) 5 (71.4) 10 (30.3)
Constipation 1 (25.0) 2 (66.7) 0 1 (20.0) 2 (28.6) 1 (14.3) 7 (21.2)
Edema 0 1 (33.3) 0 0 3 (42.9) 2 (28.6) 7 (21.2)
Abdominal pain 1 (25.0) 2 (66.7) 2 (28.6) 0 0 1 (14.3) 6 (18.2)
Headache 0 0 2 (28.6) 0 1 (14.3) 3 (42.9) 6 (18.2)
Hyponatremia 1 (25.) 0 1 (14.3) 0 2 (28.6) 2 (28.6) 6 (18.2)
Arthralgia 0 0 1 (14.3) 0 2 (28.6) 2 (28.6) 5 (15.2)
Bone pain 0 0 0 0 2 (28.6) 3 (42.9) 5 (15.2)
Diarrhea 0 0 0 0 2 (28.6) 3 (42.9) 5 (15.2)
Vomiting 0 0 0 1 (20.0) 2 (28.6) 2 (28.6) 5 (15.2)
Chills 0 0 0 0 1 (14.3) 3 (42.9) 4 (12.1)
Cough 0 0 1 (14.3) 0 2 (28.6) 1 (14.3) 4 (12.1)
Decreased appetite 2 (50.0) 0 0 0 2 (28.6) 0 4 (12.1)
Dizziness 0 0 2 (28.6) 0 1 (14.3) 1 (14.3) 4 (12.1)
Muscle spasms 1 (25.0) 0 1 (14.3) 0 0 2 (28.6) 4 (12.1)
Myalgia 0 0 1 (14.3) 0 1 (14.3) 2 (28.6) 4 (12.1)
Nasal congestion 0 1 (33.3) 1 (14.3) 0 1 (14.3) 1 (14.3) 4 (12.1)
Pain in extremity 1 (25.0) 0 0 0 0 3 (42.9) 4 (12.1)
Values shown are for the safety population (i.e., all patients who received at least one dose of LY2787106 [n = 33]). Data are n (%). Events are described using
preferred terms per MedDRA version 17.1. Patients reporting more than one adverse event were counted only once
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and 81.8 (88.29) mIU/mL, respectively.
Safety
No DLTs were reported in part A, so the MTD was
not reached. One patient in cohort B1 with liverTable 3 Mean change in hemoglobin level from baseline to end of





Mean (SD) 9.8 (0.71)
Range 8.8, 10.8
Change from baseline
to end of cycle 4
Mean (SD) −0.5 (0.49)
60% CI for meanb −0.69, −0.31
Values shown are for the evaluable population (i.e., patients in study part B who rec
CI confidence interval, SD standard deviation
aBaseline is defined as the last reported measure before first dose
bConfidence intervals are based on the t distribution. Each side of a 2-sided 60% CIadenocarcinoma experienced a non-treatment-related
adverse event (grade 3 anemia) that was declared a
stopping rule by the investigator during cycle 13. One
patient in cohort B2 with lung adenocarcinoma expe-
rienced a possibly treatment-related serious adverse
event (grade 3 cardiac failure) and a non-treatment-cycle 4
10 mg/kg
with oral iron
(cohort B2) (n = 7)
Total (n = 13)
9.5 (0.31) 9.6 (0.53)
9.0, 9.9 8.8, 10.8
−0.2 (0.80) −0.4 (0.65)
−0.53, 0.07 −0.53, −0.20
eived all four of the first four per-cycle doses of LY2787106)


































Hepcidin 10 mg/kg + iron
Hepcidin 10 mg/kg
Fig. 2 Percent change in hemoglobin level from baseline to end of
cycle 4 (week 12). Values shown are for evaluable patients in study
part B who received 10 mg/kg LY2787106 weekly (QW) without and
with oral iron (cohorts B1 [n = 6] and B2 [n = 7], respectively). Only
patients with a baseline and postbaseline result are included; for
patients who did not reach week 12, their final assessment was used
Table 4 Pharmacokinetic parameters for LY2787106 after single dos
Single dose
Study part/dose N Cmax (ng/mL) AUC0-inf (μg·h/mL) AU
Part A


































Part A (Q3W) 13
Part B (QW) 9
AUCτ,ss/AUC0-inf 13
Values for pharmacokinetic parameters are reported as geometric mean (CV%) [90%
accumulation ratios are reported as mean (CV%) [90% CI]
AUC0-inf area under the plasma concentration versus time curve to infinity after sing
the dosing interval after single dose, AUCτ,ss area under the plasma concentration v
interval, CL total body clearance, Cmax maximum observed concentration, CV% perc
elimination half-life associated with the terminal rate constant (λz), V volume of dist
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increase) during cycle 11, which together the investigator
considered a DLT-equivalent toxicity. Both patients recov-
ered from the events.
Overall, the median number of treatment cycles given
and completed was 3. Across dosing cohorts, the median
ranged in increasing order from 1 cycle in the 0.3 mg/kg
Q3W cohort (part A) to 14 cycles in cohort B2 (part B,
10 mg/kg weekly without iron).
Table 2 shows the most common treatment-emergent
adverse events overall. The majority of adverse events
were grade 1 or 2. The most common grade 3 adverse
event was fatigue (1 patient in the 1 mg/kg cohort,
2 patients in the 3 mg/kg cohort, 5 patients in cohort B1,
and all 7 patients in cohort B2). Of note, grade 3
decreased hemoglobin unrelated to treatment was re-
ported in 2 patients (both in cohort B1). Also reported
were grade 3 aspartate aminotransferase elevation (1 pa-
tient in cohort B2) and grade 1 increase in blood creatin-
ine (1 patient each in cohorts B1 and B2), none of which
were considered related to treatment. Only one grade 4
adverse event was reported (dyspnea considered unrelated
to treatment, in the 0.3 mg/kg cohort). Two patients were
discontinued from treatment, including 1 patient ine and multiple doses
Multiple dose
Cτ,sd (μg·h/mL) CL (mL/h) t1/2 (h) V (L) AUCτ,ss (μg·h/mL)
























































CI], except for t1/2 reported as geometric mean (CV%) [range]. Values for
le dose, AUCτ,sd area under the plasma concentration versus time curve over
ersus time curve during one dosing interval at steady state, CI confidence
entage coefficient of variation, Q3W every 3 weeks, QW weekly, t1/2 mean
ribution
Fig. 3 LY2787106 concentration-versus-time profile (a) and
clearance-versus-dose scatter plot (b)
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cardiac failure (left ventricular systolic dysfunction,
per NCI CTCAE terminology) and 1 patient in the
1 mg/kg cohort who died of disease progression.
Treatment-related adverse events were reported in 4
patients (12.1%), including QT prolongation (grade 1)
and neutropenia (grade 2) in 1 patient each in cohort
B1 and increased creatine phosphokinase (grade 2)
and cardiac failure (grade 3) in 1 patient each in
cohort B2.
Serious adverse events were reported in 6 patients
(18.2%), including 1 patient in the 0.3 mg/kg cohort
(dyspnea), 2 patients in the 1.0 mg/kg cohort (chondrocal-
cinosis pyrophosphate [i.e., “exacerbation of pseudogout”]
and neoplasm progression in 1 each), 2 patients in the
3 mg/kg cohort (pneumonia and arthralgia/myalgia in 1
each), and the 1 patient in cohort B2 who experienced
cardiac failure. Of these serious adverse events, only
the cardiac failure was considered possibly related to
treatment by the investigator. However, even though
the relatedness of the cardiac failure to LY2787106
could not be ruled out completely, both investigator
and sponsor considered the event more likely due to
pressure on the pulmonary artery from the patient’s
preexisting lung tumor. Two deaths were reported: one
in the 1 mg/kg cohort due to disease progression, as
noted above, and one in the 3 mg/kg cohort due to an
undetermined cause.
Eight patients generated anti-drug antibodies (ADAs)
to LY2787106, including 2 patients treated at 0.3 mg/kg,
1 patient at 1 mg/kg, 2 patients at 3 mg/kg, and 3 pa-
tients at 10 mg/kg (1 patient each in part A and in co-
horts B1 and B2). No patients had hypersensitivity
reactions. No correlation was observed between the dose
and the proportion of ADA-positive patients, and there
was no evidence that ADA positivity was linked to lower
LY2787106 exposure.
Efficacy
As shown in Table 3, the mean change in hemoglobin
level from baseline to the end of cycle 4 in part B was
−0.5 g/dL (60% CI, −0.69, 0.31) without oral iron (cohort
B1) and −0.2 g/dL (60% CI, −0.53, 0.07) with oral iron
(65–72 mg of elemental iron daily, cohort B2). A ≥0.5 g/dL
increase in hemoglobin levels was seen in 4 patients at
week 12, including 2 patients in cohort B1 (each with
multiple myeloma) and 2 patients in cohort B2 (1 with
multiple myeloma and 1 with rectal cancer). In each of
these cases, the change in hemoglobin levels was not sus-
tained and reverted to baseline. No consistent increase in
reticulocyte counts or changes in iron profiles were ob-
served in these patients. Figure 2 shows the percent
change in hemoglobin level from baseline to week 12 for
all evaluable patients.Pharmacokinetics
Pharmacokinetic parameters are summarized in Table 4.
The PK profile of LY2787106 was consistent with re-
ported PK characteristics of other mAbs; the profile in
part A included a small clearance of 32 mL/h associated
with limited volume of distribution, resulting in a t1/2 of
166 h (~7 days). As shown in Fig. 3, LY2787106 pharma-
cokinetics were independent of time and dose and ex-
posure linear in the 0.3–10 mg/kg dosing range. On the
basis of the mean t1/2 of 166 h, we calculated that mean
accumulation ratios under weekly and Q3W dosing
would be 1.98 and 1.14, respectively; the observed accu-
mulation ratios of 1.55 (21%) and 1.2 (14%) (reported as
mean [percentage coefficient of variation (CV%)]) for
part B (weekly dosing) and part A (Q3W dosing), respect-
ively, compared favorably with those estimates (Table 4).
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Pharmacodynamic data indicated that LY2787106 ad-
ministration at the highest dose (10 mg/kg) in parts A
and B led to a mean maximum 3.48-fold increase (90%
CI, 2.5–4.8) in serum iron from baseline (Fig. 4). The in-
crease in serum iron peaked at approximately 24–48 h
postdose, but returned to baseline within a week after
dosing. Although the increase in serum iron was not ac-
companied by any changes in ferritin levels indicative of
increased iron mobilization or storage (Fig. 5), it did par-
allel a transient increase in TSAT particularly at the
highest dose of 10 mg/kg (Fig. 6). Generally, the reticu-
locyte count profiles after LY2787106 administration,
represented as ratio relative to baseline, did not indicate
a consistent increase in reticulocytes. However, a transi-
ent increase in the mean ratio of reticulocyte count rela-
tive to baseline was observed at the 2-week postdose
time point in patients who received 10 mg/kg Q3W, but
relatively little change in hemoglobin levels. In addition,
an approximately 1.5- to 2-fold increase in reticulocyte
count was observed at weeks 5 to 6 in patients given the
10 mg/kg weekly dose in cohort B1. However, in part B,Fig. 4 Change in serum iron level (expressed as ratio relative to baseline) v
doses (after 5th dose). Relative_Nominal_Time (h) is the protocol-scheduled
clarity and better presentation of the earlier time point, where 168 h = 7 d
as mean ± SDnone of the 4 patients who exhibited a ≥0.5 g/dL in-
crease (albeit transient) in hemoglobin from baseline
showed any consistent increase in reticulocyte counts.
As expected, LY2787106 administration led to increased
hepcidin concentrations secondary to hepcidin binding/
neutralization by LY2787106 and hepcidin release in re-
sponse to iron increase (Fig. 7).
Other biomarkers including IL-6, TNF-α, C-reactive
protein, and erythropoietin showed no consistent trends
in their levels relative to changes in hemoglobin, hepci-
din, reticulocyte, and iron profiles.
Discussion
This is the first clinical trial of a fully humanized
mAb against hepcidin in cancer patients with anemia.
In light of hepcidin’s importance in the pathogenesis
of anemia, especially in cancer, we explored the feasi-
bility of using a mAb to target hepcidin and assess its
effect on iron and anemia. Using nonclinical data, a
PK/PD model for LY2787106 was developed to deter-
mine the starting dose for this study. The model pre-
dicted minimal to no effect at 1 mg/kg and maximalersus time course following (a) a single dose and (b) multiple weekly
time after last dose in hours presented on a log scale for greater
ays = 1 week and 336 h = 14 days = 2 weeks. Data are displayed
Fig. 5 Change in ferritin level (expressed as ratio relative to baseline) versus time course following (a) a single dose and (b) multiple weekly doses
(after 5th dose). Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and
better presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD
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levels ranging from 0.3 to 10 mg/kg administered
Q3W were selected for part A of the study.
Patients treated in the four dosing cohorts during the
dose-escalation phase (part A) of this study tolerated the
treatment well, as evidenced by the absence of DLTs and
grade ≥3 treatment-related adverse events. Interim data
from the study demonstrated a significant increase in
serum iron levels at the 10 mg/kg dose level within 24 h
after LY2787106 infusion (see Additional file 1: Figure S1).
However, the increase in serum iron levels was transi-
ent and returned to baseline in less than 8 days. These
findings coincided with inconsistent response in reticu-
locyte count and hemoglobin levels in the patients
treated in part A.
In part B of the study, only approximately half of the
planned 24 patients were enrolled, mainly because of
slow accrual. The safety and tolerability of LY2787106observed in part A were further confirmed by the rela-
tive infrequency of treatment-emergent adverse events,
which were primarily grade 1/2 in severity. Serum iron
and TSAT increased a few hours after administration of
LY2787106, which confirmed that the administration of
10 mg/kg LY2787106 adequately neutralized hepcidin.
However, these changes remained transient and did not
affect ferritin levels, hemoglobin values, or reticulocyte
counts in either dosing group despite the increase to
once weekly dosing and the addition of supplemental
oral iron in cohort B2. Similar observations regarding
serum iron and TSAT were made in a study of an anti-
hepcidin pegylated structured mirror-image oligoribo-
nucleotide, lexaptepid pegol, in healthy patients [10]. In
that study, however, an increase in serum ferritin levels
from baseline was seen with lexaptepid pegol that was
not seen in the present study with LY2787106. This dif-
ference may be due to elevated baseline serum ferritin
Fig. 6 Transferrin saturation (percentage) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th
dose). Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better
presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD
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founding factors such as concomitant chemotherapy [11].
In addition, the lack of sustained mobilization of serum
iron may have contributed to the lack of changes in serum
ferritin levels.
Several factors may have contributed to the lack of
hematologic response in this study: the unsustained in-
crease in serum iron levels despite weekly dosing, mye-
losuppression due to concomitant chemotherapy, the
relative frequency of phlebotomies on study, the pres-
ence of comorbidities that could have interfered with
erythropoiesis, and the heterogeneity of cancer types
with distinct inflammatory profiles [12]. Circadian
changes may also have influenced the complex regula-
tion between serum iron and hepcidin levels. Other
studies have shown elevated levels of cytokines such as
IL-6 in cancer patients with anemia [13], which may
contribute to a lack of significant response in erythropoi-
esis and to an increase in hepcidin expression levels
[14]. Therefore, neutralizing hepcidin alone may not besufficient to induce robust and sustained elevation of
hemoglobin and reticulocytes in patients with cancer.
Furthermore, compensatory increase in the hepcidin
levels may also explain the lack of significant response in
hemoglobin levels. The incomplete enrolment in part B
due to slow accrual may have limited the number of pa-
tients evaluable for hematological changes. However, its
impact on the overall findings is minimal compared with
the effects of other confounding factors as mentioned
previously.
The lack of a consistent reticulocyte and hemoglobin
response in this study also led us to investigate whether
the dose we used was appropriate. We did this by exam-
ining the target inhibition in terms of hepcidin/
LY2787106 ratios in two possible scenarios. In the first
scenario, which assumed that each drug molecule bound
only one hepcidin molecule, we observed mean (90% CI)
hepcidin/LY2787106 ratios of 0.5 (0.23–1.48), 1.6 (1.2–2.2),
and 1.3 (0.83–1.73) at 24, 72, and 168 h, respectively,
postdose. In the second scenario, which assumed that each
Fig. 7 Hepcidin (ng/mL) concentration-versus-time profile following (a) a single dose and (b) multiple weekly doses (after 5th dose).
Relative_Nominal_Time (hr) is the protocol-scheduled time after last dose in hours presented on a log scale for greater clarity and better
presentation of the earlier time point, where 168 h = 7 days = 1 week and 336 h = 14 days = 2 weeks. Data are displayed as mean ± SD
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mean ratios of 0.25 (0.115–0.74), 0.8 (0.6–1.1), and 0.65
(0.415–0.865) at 24, 72, and 168 h, respectively. Since most
of the CIs around these mean ratio values were below or in-
cluded 1, we postulate that the 10 mg/kg dose of
LY2787106 was likely sufficient to significantly neutralize
hepcidin. This hypothesis is true under the assump-
tion, albeit unverified, that the hepcidin/LY2787106
ratios in serum are an adequate surrogate to the ratio
at the level of the site of action of hepcidin (i.e., the
level of the ferroportin receptor). The significant in-
crease in iron and TSAT levels at the 10 mg/kg dose
of LY2787106 further supports that hypothesis. One
strategy for testing the hypothesis would have been to
escalate the LY2787106 dose beyond 10 mg/kg to de-
termine whether or not the pharmacological response
was optimal/maximal at 10 mg/kg. However, we didnot do so because we expected to see an improve-
ment in PD response with weekly (as opposed to
Q3W) dosing if the optimal PD effect had not been
reached at 10 mg/kg. Indeed, despite the significantly
higher accumulation of LY2787106 under weekly ver-
sus Q3W dosing (see Table 4), the changes in iron
levels were very similar after LY2787106 administra-
tion for both dosing intervals (weekly and Q3W).Conclusions
In conclusion, LY2787106 was well tolerated in cancer
patients with anemia. Targeting the hepcidin-ferroportin
pathway by neutralizing hepcidin resulted in transient
iron mobilization and reticulocyte count relative to base-
line, thus supporting the role of hepcidin in iron regula-
tion. Agents that affect other relevant targets in the
Vadhan-Raj et al. Journal of Hematology & Oncology  (2017) 10:73 Page 12 of 12hepcidin-ferroportin pathway such as ferroportin are
currently being evaluated.
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